Prevalence and Impact of Comorbidity Burden in Patients Referred for Screening Colonoscopy
Screening colonoscopy has been shown to reduce mortality from colorectal cancer (CRC) by the removal of premalignant adenomas (1). Yet the benefit from screening colonoscopy decreases with advancing age due to increasing comorbidities (2). Currently, there are several societies who provide general recommendations primarily surrounding age and life expectancy to help clinicians determine if screening colonoscopy will have a mortality benefit. Yet a recent study predicted ~40% of patients who completed colonoscopy likely had less than a 10-year life expectancy (3). The Charlson Comorbidity Index (CCI) uses 22 comorbid conditions to prognosticate a patient’s comorbid burden at 1 and 10 years (4). The CCI and validated algorithms based on ICD codes have been utilized to independently predict mortality outcomes in a few diseases (5-7). A previous study using CCI to evaluate perioperative colorectal cancer mortality found that patients with a score of 7 were at significantly increased risk for mortality (8). Yet the prevalence of comorbidities as defined by the CCI for patients referred for screening colonoscopy has not been fully evaluated. Therefore, we aim to 1) determine the prevalence of patients with a CCI score greater than 7 who have undergone a screening or surveillance- 1 Generated on IRBNet colonoscopy and 2) determine the average CCI score for patients who have died less than 5 years after undergoing screening/surveillance colonoscopy.
principal Investigator: Dr. Gregory Sayuk
To learn more this study and how you can join contact our research office at (314) 289-7690
To learn more this study and how you can join contact our research office at (314) 289-7690